Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Research Brief: Reelin Loss Ramps Up Aβ Pathology
16 July 2010. The protein reelin helps rein in pathology in Alzheimer disease mice, according to a recent report which comes on the heels of related findings presented at “ApoE and ApoE Receptors in Neurodegeneration,” a one-day symposium held 7 June 2010 in St. Louis, Missouri. At that meeting, Edwin Weeber, University of South Florida, Tampa, reported that reelin restores synaptic plasticity in hippocampal slices from amyloid precursor protein (APP) transgenic mice, while Joachim Herz, University of Texas Southwest Medical Center, Dallas, outlined how the protein rescues Aβ toxicity in an ApoE isoform-dependent manner. Reelin, an ApoE receptor ligand, restores long-term potentiation in Aβ-treated hippocampal slices if they have an ApoE2 or ApoE3 background, but not in ApoE4-positive tissue (see ARF related news story).

Now, the new work, described in the July 7 Journal of Neuroscience, reinforces the reelin connection. Researchers led by Irene Knuesel at the University of Zurich, Switzerland, report that Aβ and tau pathology are amplified when transgenic APP695 mice are crossed with reeler (reln) mice, which lack one copy of the reelin gene. Joint first authors Samira Kocherans and Amrita Madhusudan and colleagues found that Aβ plaques appear in App/reln mice as early as six months of age, three months before they emerge in the APP parent strain. Furthermore, the density of large plaques in the hippocampus and cerebral cortex was greater in nine-month-old APP/reln crosses than age-matched APP controls. The authors attribute the early and exacerbated plaque pathology to more rampant amyloidogenic processing of APP, since they detected much more soluble Aβ40/42 and more β-secretase-derived C-terminal APP fragments in the hippocampus and cortex of the APP/reln mice.

The lack of reelin had further reaching effects, including activation of microglia and astrocytes and elevation of tau phosphorylation. Tau phosphorylation was particularly evident in the vicinity of Aβ plaques in 15-month-old APP/reln mice. In these aged animals, the authors also found evidence of dystrophic neurites and neurofibrillary tangles, which are generally not found in APP transgenic mice. “Together, the findings indicate that a genetic reduction in reelin expression accelerates the production of amyloidogenic Aβ peptides, which results in earlier plaque formation and an age-related aggravation of the pathology, including early signs of neurodegeneration...,” write the authors. Given that reelin also rescues the inhibitory effects of Aβ on synaptic plasticity, as described at the St. Louis meeting, it appears that the protein not only retards production of Aβ, but its toxicity as well, which makes it an interesting candidate for further study.—Tom Fagan.

Reference:
Kocherhans S, Madhusudan A, Doehner J, Breu KS, Nitsch RM, Fritschy JM, Knuesel I. Reduced Reelin expression accelerates amyloid-beta plaque formation and tau pathology in transgenic Alzheimer's disease mice. J Neurosci. 2010 Jul 7;30(27):9228-40. Abstract

 
  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad